Insmed Incorporated (NASDAQ:INSM) is Emerald Advisers LLC’s 6th Largest Position

Emerald Advisers LLC decreased its holdings in Insmed Incorporated (NASDAQ:INSM) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 684,636 shares of the biopharmaceutical company’s stock after selling 5,171 shares during the quarter. Insmed comprises approximately 1.8% of Emerald Advisers LLC’s portfolio, making the stock its 6th biggest holding. Emerald Advisers LLC owned about 0.38% of Insmed worth $47,267,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC raised its position in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 163 shares in the last quarter. V Square Quantitative Management LLC raised its position in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 248 shares in the last quarter. Spire Wealth Management purchased a new position in Insmed in the fourth quarter worth $47,000. Smartleaf Asset Management LLC raised its position in Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC purchased a new position in Insmed in the fourth quarter worth $86,000.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Guggenheim restated a “buy” rating and issued a $101.00 price target on shares of Insmed in a research report on Tuesday, February 25th. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, February 21st. Stifel Nicolaus dropped their price target on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Bank of America raised their price target on Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $94.00.

Insmed Stock Up 1.5 %

Shares of NASDAQ:INSM opened at $79.92 on Friday. The stock’s 50-day moving average price is $77.43 and its two-hundred day moving average price is $73.80. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The firm has a market cap of $14.47 billion, a price-to-earnings ratio of -14.30 and a beta of 1.28.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. On average, research analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Transactions at Insmed

In other news, insider Martina M.D. Flammer sold 3,344 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the transaction, the insider now directly owns 102,766 shares in the company, valued at $6,773,307.06. This trade represents a 3.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50. Following the completion of the transaction, the chief executive officer now owns 334,186 shares in the company, valued at approximately $25,742,347.58. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock worth $42,992,528 in the last three months. 4.60% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.